News

25
Oct

Genoskin granted new patent on subcutaneous injection model

Genoskin granted a new patent on ex vivo subcutaneous injection model The French National Institute for Intellectual Property (INPI) granted Genoskin's latest patent on its unique ex vivo subcutaneous injection model, HypoSkin®. A boom in the subcutaneous biologics market Today, subcutaneous injection is one of the most common methods to deliver a drug into the human body. Its use has increased significantly
Read more
18
Sep

PRESS RELEASE – Genemarkers and Genoskin announce new partnership

Genemarkers and Genoskin are pleased to announce they have formed a partnership to provide exceptional value and service to researchers in the fields of cosmetic and pharmaceutical topical solutions. The Companies are currently performing collaborative work to understand how cannabidiol (CBD) acts in the skin.

26
Sep

Genoskin signs distribution agreement with Japanese distributor

Genoskin signs distribution agreement with Japan's Fujifilm Wako Pure Chemical The Genoskin team is excited to announce that we've signed an agreement with the Japanese Fujifilm Wako Pure Chemical Corporation to distribute Genoskin's ex vivo human skin models to customers in Japan. This agreement will enable Genoskin to respond to the specific needs of exisiting and potential customers in Japan and to increase its
Read more
6
Sep

New study model for injectable anti-psoriasis drugs

New study model for injectable anti-psoriasis drugs A hi-tech psoriasis skin model to study drug efficacy To evaluate the efficacy of injectable anti-psoriasis drugs, the Genoskin team has designed a new test model that combines the InflammaSkin® and HypoSkin® technologies. Below you’ll find a proof-of-concept case study that illustrates the relevance of the new Hypo-InflammaSkin® model during efficacy studies of injectable
Read more
22
Feb

Ex vivo human skin models for cosmetic testing

Standardized ex vivo skin models for cosmetic testing Cosmetic testing is playing an increasingly important role in today’s cosmetic industry. The first cosmetic tests took place in 1933, after an eyelash darkening treatment blinded several women. In 1938, the U. S. Food and Drug Administration passed the Federal Food, Drug & Cosmetic (FD&C) Act to define stricter regulations for cosmetic products
Read more
15
Feb

Genoskin develops new perfusable vascularized skin model

New ex vivo perfusable vascularized human skin model for drug testing Perfusable vascularized skin for increased viability and optimal skin response Natural human skin contains a rich vascular network, which is essential for the transport and absorption of nutrients and drugs. However, a key drawback of currently engineered human skin models is their lack in vascularization. Recreating a vascularization in
Read more